Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

NCT00604383 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

685

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Retinopathy

Interventions

DRUG: ruboxistaurin
DRUG: placebo

Sponsor

Chromaderm, Inc.